Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., developed "Mei Asha Tan Potassium Tablets," which have received regulatory approval for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" medications play a crucial role within the family of antihypertensive drugs, indicating strong market demand and potential for growth in this segment [1]

Core Insights - The company has received approval from the National Medical Products Administration of China for its product "Mebsartan Potassium Tablets" (trademark: Kuanopeng), which is indicated for the treatment of primary hypertension [1][2] - "Mebsartan Potassium" is a significant addition to the company's product pipeline in the cardiovascular system sector, providing more treatment options for adult patients with primary hypertension [2] Group 1: Product Details - "Mebsartan Potassium" is an angiotensin II receptor antagonist that converts rapidly to its active form, Azilsartan, after oral administration, effectively lowering blood pressure by blocking angiotensin II hormone [1] - The product is classified as a Category B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults [1] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting its importance in the hypertension drug family [1] - The company’s "Mebsartan Potassium Tablets" are available in 40mg and 80mg dosages, catering to both mild to moderate and severe hypertension patients [2]